Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, which is more or less 9.11 % above the existing share price of $76.07.
Cherny expects CVS Health Corp to publish earnings per share (EPS) of $0.93 for the very first quarter of 2021.
The analysts priced targets range from a high of $101 to a low of $61.
From its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is actually $99.57 billion.
According to TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with 4 stars on a 0 5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management strategies. The Long or retail Term Care segment has offering of prescription medications as well as assortment of general merchandise.
The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and related services, which includes medical, pharmacy, dental, behavioural health, healthcare control capabilities. The Corporate segment involves in providing administrative services as well as management. The company was developed by Stanley P. Goldstein and Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.